Advertisement #1
Home Tags Sacituzumab Govitecan

Tag: Sacituzumab Govitecan

US FDA Approves Gilead’s Sacituzumab Govitecan In Pre-treated HR+/HER2- Metastatic Breast...

Editorial Team -
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2022: Sacituzumab Govitecan Show PFS Benefits in Patients Diagnosed with...

Danielle Garcia -

Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...

Peter Hofland -

ESMO 2020: Sacituzumab Govitecan Shows 27% ORR in Heavily-pretreated Metastatic Urothelial...

Editorial Team -

Confirmatory Phase III ASCENT Study Shows Significant Improved Overall Survival in...

Danielle Garcia -
Triple negative breast cancer cells showing abnormal expression basal-like markers not found on normal breast epithelial cells. Cells are stained with cytokeratins 14 (green) and 19 (red). Photo courtesy: Bill Schmitt.

ESMO 2020: Sacituzumab Govitecan Significantly Extends Overall Survival in Patients with...

Editorial Team -

ESMO 2020: Encouraging Early-Stage Clinical Results with Sacituzumab Govitecan in Brain...

Editorial Team -

New Therapies may Offer Hope for Patients with Metastatic Breast Cancer

Peter Hofland -
Watching a mammogram-the result of x-ray examination of the mammary glands for the prevention of breast cancer. Courtesy: Fotolia/Evgeniy Kalinovskiy

Sacituzumab Govitecan Approved in Metastatic Triple-negative Breast Cancer

Peter Hofland -
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: Sacituzumab Govitecan in Metastatic Urothelial Cancer and Breast Cancer

Peter Hofland -

LATEST NEWS

Advertisment #12
© 2001 - 2023 Sunvalley Communication, LLC. All Rights Reserved.

X